IC₅₀values for bosutinib, imatinib, dasatinib, and nilotinib against 18 mutations of the Bcr-Abl sequence expressed in Ba/F3 transfected cells. IC₅₀, relative concentration of the compound that inhibits 50% of the enzymes activity; WT, wild type; P loop, phosphate-binding loop; ATP, adenosine triphosphate; SH2, Src homology 2; A loop, activation loop.
 This table was originally presented in the Journal of Clinical Oncology. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27:479–471. The data is also available at www.ilte-cml.org/TKI-table.pdf. © The Journal of Clinical Oncology.